HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

PGNY

Progyny, Inc. (NASDAQ)

Healthcare — Healthcare Plans

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Strong Buy 1.4 / 5 11 analysts
$29.45
+$0.62 (+2.15%)
Target: $30.00 (1.9%)
Sign in to add PGNY to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$2.31B
P/E Ratio (TTM)38.25
Forward P/E13.35
EPS (TTM)$0.77
Dividend Yield-
Profit Margin5.24%
Revenue Growth1.40%
ROE14.94%
Debt/Equity6.21
Recommendation Strong Buy 1.4
Analyst Target$30.00
Analysts11
Indexes NASDAQ

Technical Indicators

RSI (14)80.9
Beta1.04
SMA 20-
SMA 40-
52-Week High$30.10
52-Week Low$16.10
50-Day Avg$23.83
200-Day Avg$22.28
Avg Volume$1.53M
Volume$1.45M

Performance Analysis

NEUTRAL

PGNY presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($30.10), which may indicate limited upside.
- RSI at 80.9 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 1.4% year-over-year.
+ Wall Street consensus is "Strong Buy" from 11 analysts.
+ Average analyst target of $30.00 implies 1.9% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:26 UTC

Back to Screener Export Report